CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that Eric S. Hoffman has joined the company as chief business officer.
"I am delighted to welcome Eric to Genocea at such an exciting time for the company as we progress our Phase 2 programs for the large genital herpes and pneumococcal markets"
"I am delighted to welcome Eric to Genocea at such an exciting time for the company as we progress our Phase 2 programs for the large genital herpes and pneumococcal markets," said Chip Clark, president and chief executive officer of Genocea. "Eric brings proven business development credentials and deep industry and infectious disease experience to our team."
Prior to joining Genocea, Eric was vice president of corporate and business development, program management and commercial operations at Idenix Pharmaceuticals, Inc. before its acquisition by Merck in August 2014. Eric also held roles in investor relations and corporate communications whilst at Idenix. Prior to Idenix, Eric spent four years at Biogen Idec in investor relations and business development roles and spent six years on Wall Street as an equity research analyst at J.P. Morgan, Schwab Soundview Capital Markets and Bear Stearns. Before starting on Wall Street in 2001, he was a post-doctoral research scientist in the Department of Immunobiology at Guy's Hospital in London, studying T cell development. He has authored several book chapters and peer-reviewed papers, including in Cell, Immunity, and Genes & Development. He holds a Ph.D. in Immunobiology from Yale University and a B.S. in Biology from Trinity University.
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immune response. Using ATLAS™, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs. Genocea's pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for HSV-2 therapy, GEN-004 to prevent infections caused by pneumococcus, and earlier-stage programs in chlamydia, HSV-2 prophylaxis, malaria and cancer immunotherapy. For more information, visit www.genocea.com.